Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.44 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.44 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.44 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775134 | 0.84 | GPR119 (0.66) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL942134 | 0.83 | MMP1 (0.49) | GPR119FPR2PROKR1MMP1LIPE | |
| SCHEMBL943749 | 0.81 | MMP1 (0.56) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL941602 | 0.80 | MMP13 (0.49) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL941217 | 0.80 | GPR119 (0.49) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL941663 | 0.79 | MMP1 (0.47) | GPR119FPR2PROKR1MMP1LIPE | |
| Hydrochloric Acid SCHEMBL6803226 | 0.79 | GPR119 (0.48) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL941398 | 0.79 | MMP1 (0.54) | GPR119FPR2PROKR1MMP1CACNB4 | |
| SCHEMBL5672385 | 0.79 | GPR119 (0.58) | GPR119MMP1CACNB4CACNA1ACACNA1G | |
| SCHEMBL5672367 | 0.79 | GPR119 (0.58) | GPR119MMP1CACNB4CACNA1ACACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GPR119 4482/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GPR119 4482/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GPR119 4482/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | GPR119 4215/4885FPR2 1510/4885PROKR1 2106/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | GPR119 2739/4885FPR2 1887/4885PROKR1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.